Orexo Interim Report Q3 2022
Advancing the pipeline facilitating future growth Q3 2022 highlights · Total net revenues of SEK 161.0 m (145.9) · EBITDA of SEK -32.4 m (-47.4), EBITDA excluding legal costs and costs for non-repeating clinical trials, SEK 14.3 m (-13.4) · Net earnings of SEK -26.5 m (-52.0) · US Pharma segment (ZUBSOLV[®] US) net revenues of SEK 150.1 m (136.4), in local currency USD 14.2 m (15.8), US Pharma EBIT of SEK 70.2 m (78.5) · Cash flow from operating activities of SEK -60.7 m (-79.7), cash and invested funds of SEK 443.9 m (588.1) a reduction of SEK 23,8 m from SEK 467.7 m